<DOC>
	<DOCNO>NCT00317096</DOCNO>
	<brief_summary>The aim phase III trial ass safety efficacy treatment rituximab combination FCM chemotherapy ( R-FCM ) versus FCM chemotherapy alone remission induction asses safety efficacy rituximab maintenance versus observation response induction therapy . Both question address way prospective randomize comparison patient relapse FL , MCL LP lymphoma .</brief_summary>
	<brief_title>FCM Versus R-FCM Followed R-Maintenance Observation Only</brief_title>
	<detailed_description>Patients relapse centroblastic/centrocytic ( FL ) , centrocytic ( MCL ) lymphoplasmacytoid lymphoma randomly assign either FCM chemotherapy alone FCM chemotherapy combination monoclonal anti-CD20 antibody rituximab ( R-FCM ) . FCM chemotherapy give 4 cycle interval 4 week . In patient assigned cytoreductive therapy FCM plus rituximab , monoclonal antibody give one infusion ( 375 mg/m2 ) day respective FCM course total four application . Four week end FCM chemotherapy patient CR PR randomly assign either treatment maintenance therapy rituximab . Rituximab give 4 time ( one infusion per week 375 mg/m2 ) . After six month rituximab treatment repeat another 4 infusion . In case relapse patient receive alternative treatment accord decision investigator . The aim phase III trial ass safety efficacy treatment rituximab combination FCM chemotherapy versus FCM chemotherapy alone remission induction asses safety efficacy rituximab maintenance versus observation response induction therapy . Both question address way prospective randomize comparison patient relapse FCL , MCL LP lymphoma . Primary objective trial compare ( 1 ) remission rate ( CR PR ) achieve FCM plus rituximab versus FCM alone ( 2 ) progression free interval rituximab maintenance versus observation .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Inclusion Criteria patient histologically proven stage III/IV centroblastic/centrocytic ( FL ) , centrocytic ( MCL ) lymphoplasmacytoid lymphoma ( LPIC ) . relapse disease initial chemotherapy peripheral blood stem cell transplantation twodimensionally measurable lesion outside previously irradiate area ( osteoblastic bone lesion , ascites , pleural effusion evaluable ) age &gt; 18 year Karnofskyindex &gt; 60 life expectancy least 3 month effective contraception female premenopausal patient patient 's write informed consent age &lt; 18 year Karnofskyindex &lt; 60 treatment fludarabine mitoxantrone within precede three month active autoimmune hemolytic anemia start FCM chemotherapy participation another clinical trial last 4 week participation study previous treatment murine antibody concurrent disease exclude administration therapy outline study protocol noncompensated heart failure dilatative cardiomyopathy coronary heart disease ST segment depression ECG myocardial infarction last 6 month chronic lung disease hypoxemia severe noncompensated hypertension severe noncompensated diabetes mellitus renal insufficiency ( creatinine &gt; 2.0 mg/dl ) , related lymphoma hepatic insufficiency transaminase value great 3fold normal value and/or bilirubin level &gt; 2.0 mg/dl , relate lymphoma clinical sign cerebral dysfunction woman lactation pregnancy childbearing potential use reliable contraceptive method severe psychiatric disease serological positivity HBV , HCV , HIV previous organ transplantation autologous peripheral blood stem cell transplantation miss write informed consent miss write consent data protection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Drug Therapy</keyword>
	<keyword>Maintenance</keyword>
	<keyword>rituximab</keyword>
</DOC>